MDCO - The Medicines Company

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

The Medicines Company

8 Sylvan Way
Parsippany, NJ 07054
United States

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees62

Key Executives

NameTitlePayExercisedYear Born
Mr. Mark TimneyCEO & Director86.54kN/A1965
Mr. Christopher J. VisioliCFO & Treasurer528.05kN/A1976
Mr. Stephen M. Rodin J.D.Exec. VP, Gen. Counsel & Sec.657.05kN/A1976
Dr. Clive A. MeanwellChief Innovation Officer & Director1.21MN/A1958
Dr. Goutham Krishna GortiVP & Head of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.

Corporate Governance

The Medicines Company’s ISS Governance QualityScore as of October 4, 2019 is 4. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 4; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.